Retatrutide Dosing Determination
Retatrutide dosing is not determined by patient body weight. (nejm.org)
Retatrutide is administered as fixed once-weekly subcutaneous doses with protocol-defined dose-escalation regimens. (nejm.org)
Dosing Regimens Used in Phase 2 Studies
Phase 2 obesity trial dosing used maintenance dose arms of 1 mg, 4 mg, 8 mg, and 12 mg once weekly with protocol-defined initial dosing (e.g., 4 mg arms started at 2 mg or 4 mg). (nejm.org)
Phase 2 type 2 diabetes trial dosing used once-weekly injections with protocol-defined maintenance doses of 0.5 mg, 4 mg, 8 mg, and 12 mg with escalation starting from lower doses (e.g., 4 mg maintenance started at 2 mg). (pubmed.ncbi.nlm.nih.gov)
Weight-Based Dosing Not Used
Randomization in the phase 2 type 2 diabetes trial used stratification for baseline HbA1c and BMI, which does not constitute weight-based dosing. (pubmed.ncbi.nlm.nih.gov)
The phase 2 obesity trial assigned participants to specific retatrutide dose-escalation strategies, which were not described as functions of individual body weight. (nejm.org)
Clinical Practical Implication
Dose selection in retatrutide studies is based on the assigned fixed maintenance dose and protocol-defined titration schedule rather than on adjusting dose by body weight. (nejm.org)